TIL
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.
Instil Bio, Inc. (TIL) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (D+). The rating has held at C for 9 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-15 | C+ (2.5) | C+ (2.5) | D+ (1.6) | C- (2.1) | C+ (2.6) | C (2.3) |
| 2026-11-08 | C+ (2.5) | C+ (2.5) | D+ (1.6) | C (2.3) | C+ (2.6) | C (2.3) |
| 2026-11-01 | C+ (2.5) | C+ (2.5) | D+ (1.6) | C (2.5) | C+ (2.7) | C (2.4) |
| 2026-10-25 | C+ (2.5) | C+ (2.5) | D+ (1.6) | C- (2.0) | C+ (2.6) | C (2.3) |
| 2026-10-18 | C+ (2.5) | C+ (2.5) | D+ (1.6) | C- (1.9) | C+ (2.6) | C (2.2) |